Stevenson, M., Lloyd Jones, M., De Nigris, E., Brewer, N., Davis, S., Oakley, J.
Objectives: To establish the clinical effectiveness and cost-effectiveness of selective oestrogen receptor modulators, bisphosphonates and parathyroid hormone (subject to licensing) for the...
Stevenson, M., Lloyd Jones, M., De Nigris, E., Brewer, N., Davis, S., Oakley, J.
Objectives: To establish the clinical effectiveness and cost-effectiveness of selective oestrogen receptor modulators, bisphosphonates and parathyroid hormone (subject to licensing) for the...
Stevenson, M., Lloyd Jones, M., De Nigris, E., Brewer, N., Davis, S., Oakley, J.
Objectives: To establish the clinical effectiveness and cost-effectiveness of selective oestrogen receptor modulators, bisphosphonates and parathyroid hormone (subject to licensing) for the...
Treatment of established osteoporosis: a systematic review and cost–utility analysis (2003)
Kanis, J.A., Brazier, J.E., Stevenson, M., Calvert, N.W., Lloyd Jones, M.
Chilcott, J., Lloyd Jones, M., Wight, J., Forman, K., Wray, J., Beverley, C., ...
Background: Haemolytic disease of the newborn affects the fetus or neonate, and results from the transplacental passage of maternal allo-antibodies directed against fetal red cell antigens inherited...
Treatment of established osteoporosis: a systematic review and cost-utility analysis (2003)
Kanis, J.A., Brazier, J.E., Stevenson, M., Calvert, N., Lloyd Jones, M.
Background and aims Osteoporosis is a systemic skeletal disease, characterised by low bone mass and microarchitectural deterioration of bone tissue with a subsequent increase in bone fragility and...
Treatment of established osteoporosis: a systematic review and cost–utility analysis (2003)
Kanis, J.A., Brazier, J.E., Stevenson, M., Calvert, N.W., Lloyd Jones, M.
Chilcott, J., Lloyd Jones, M., Wight, J., Forman, K., Wray, J., Beverley, C., ...
Background: Haemolytic disease of the newborn affects the fetus or neonate, and results from the transplacental passage of maternal allo-antibodies directed against fetal red cell antigens inherited...
Treatment of established osteoporosis: a systematic review and cost-utility analysis (2003)
Kanis, J.A., Brazier, J.E., Stevenson, M., Calvert, N., Lloyd Jones, M.
Background and aims Osteoporosis is a systemic skeletal disease, characterised by low bone mass and microarchitectural deterioration of bone tissue with a subsequent increase in bone fragility and...
Treatment of established osteoporosis: a systematic review and cost–utility analysis (2003)
Kanis, J.A., Brazier, J.E., Stevenson, M., Calvert, N.W., Lloyd Jones, M.
Chilcott, J., Lloyd Jones, M., Wight, J., Forman, K., Wray, J., Beverley, C., ...
Background: Haemolytic disease of the newborn affects the fetus or neonate, and results from the transplacental passage of maternal allo-antibodies directed against fetal red cell antigens inherited...
Treatment of established osteoporosis: a systematic review and cost-utility analysis (2003)
Kanis, J.A., Brazier, J.E., Stevenson, M., Calvert, N., Lloyd Jones, M.
Background and aims Osteoporosis is a systemic skeletal disease, characterised by low bone mass and microarchitectural deterioration of bone tissue with a subsequent increase in bone fragility and...
Chilcott, J., Wight, J., Lloyd Jones, M., Tappenden, P.
Background Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in insulin secretion and action. The resulting build-up of glucose in the blood can cause a range of...
Chilcott, J., Wight, J., Lloyd Jones, M., Tappenden, P.
Background Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in insulin secretion and action. The resulting build-up of glucose in the blood can cause a range of...
Chilcott, J., Wight, J., Lloyd Jones, M., Tappenden, P.
Background Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in insulin secretion and action. The resulting build-up of glucose in the blood can cause a range of...
Lloyd Jones, M., Hummel, S., Bansback, N., Orr, B.
Background Description of proposed service: The service evaluated in this review is the use of irinotecan, oxaliplatin and raltitrexed, as both monotherapy and combination therapy, in the first- and...
Lloyd Jones, M., Hummel, S., Bansback, N., Orr, B.
Background Description of proposed service: The service evaluated in this review is the use of irinotecan, oxaliplatin and raltitrexed, as both monotherapy and combination therapy, in the first- and...
Lloyd Jones, M., Hummel, S., Bansback, N., Orr, B.
Background Description of proposed service: The service evaluated in this review is the use of irinotecan, oxaliplatin and raltitrexed, as both monotherapy and combination therapy, in the first- and...